Credit: Arcutis. Zoryve cream contains roflumilast, a phosphodiesterase type 4 inhibitor. Zoryve (roflumilast) cream 0.15% is now available for the topical treatment of mild to moderate atopic ...

More patients treated with Vtama achieved vIGA-AD success compared with those who received vehicle cream in both ADORING 1 (45% vs 14%) and ADORING 2 (46% vs 18%). The Food and Drug Administration ...

Still itching after topical steroids? Here's why your atopic dermatitis symptoms may still be flaring and what you can do about it.

Libtayo's approval for high-risk cutaneous squamous cell carcinoma offers a new immunotherapy option, targeting PD-1 ...

Here are our top highlights from AAD 2025 that include safety of topical JAK inhibitors, climate impacts on skin health, ...

Once-daily roflumilast cream at 0.15% improved symptoms of atopic dermatitis (AD) across multiple end points. According to investigators of the phase 3 studies that uncovered the findings, roflumilast ...

Due to eczema, asthma and allergies being so closely connected, coordinated care plays a critical role in long-term outcomes. Allergists are uniquely trained to manage these conditions together rather ...

Atopic dermatitis is the most common type of eczema, affecting approximately 9.6 million children in the U.S. WESTLAKE VILLAGE, Calif., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. More than a quarter of patients achieved a clear or ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. AD affected more than 35% body surface area of study ...

Dong-A ST announced on December 15 that it has signed an exclusive domestic distribution and sales agreement with Menarini ...